Effects of 50- or 60-hertz, 100 microT magnetic field exposure in the DMBA mammary cancer model in Sprague-Dawley rats: possible explanations for different results from two laboratories. by Anderson, L E et al.
Environmenta
l
Effects of 50- or 60-Hertz, 100 µT Magnetic Field Exposure in the DMBA
Mammary Cancer Model in Sprague-Dawley Rats: Possible Explanations for
Different Results from Two Laboratories
Larry E. Anderson,1 James E. Morris,1 Lyle B. Sasser,1 and Wolfgang Löscher2
1Environmental and Health Sciences Division, Battelle, Richland, Washington, USA; 2Department of Pharmacology, Toxicology and
Pharmacy, School of Veterinary Medicine, Hannover, Germany
Electric and magnetic ﬁelds (MF) associated
with the production, transmission, and use
of electricity are ubiquitous in industrialized
societies. There is an ongoing controversy
about whether exposure to power-line fre-
quency (50- or 60-Hz) MF is a risk factor
for cancer (1–4). Interest in this question
has been triggered primarily by epidemio-
logic studies that have suggested an associa-
tion between 50- or 60-Hz MF exposure
and increased risk of childhood leukemia
(2). Furthermore, on the basis of earlier
work reporting the effects of 60-Hz electric
ﬁelds on melatonin levels, a hypothesis was
developed stating that exposure to power
line-frequency MF could be a risk factor for
breast cancer (5). Because of the universal
exposure to power-line-frequency MF and
the increasing breast cancer rates in industri-
alized countries, this possible relationship
between electric power and breast cancer
risk as well as the underlying melatonin
hypothesis has attracted much interest.
Several epidemiologic and experimental
studies have been conducted to study the
effects of MF on breast cancer (6). So far
the epidemiologic data are equivocal, but
several occupational studies found a signiﬁ-
cantly increased relative risk of breast cancer
in women by MF exposure in the low
microtesla range (7). To assess the potential
of MF to inﬂuence the process of mammary
carcinogenesis, epidemiologic studies have
been supplemented with controlled labora-
tory studies. The first experimental study
using a rat mammary carcinoma model was
published by Beniashvili et al. (8), who
reported an increased incidence of mamma-
ry adenocarcinomas in nitrosomethylurea-
treated rats (strain unspeciﬁed) exposed for
3 hr/day for 2 years to a 50-Hz MF of 20
µT. Most experimental work on the electric
power/breast cancer hypothesis is from
Löscher et al. (9,10) in Hannover,
Germany, using 50-Hz MF exposure in the
well-established 7,12-dimethylbenz[a]anthra-
cene (DMBA) rat model of mammary
carcinogenesis (9,10). In a series of experi-
ments in female Sprague-Dawley (SD) rats,
the authors found that, consistent with the
melatonin hypothesis, prolonged exposure
to 50-Hz MF at flux densities in the
microtesla range decreases nocturnal mela-
tonin plasma levels, increases the activity of
ornithine decarboxylase (ODC) in breast
tissue, impairs immune surveillance, and en-
hances mammary tumor development and
growth in response to the chemical carcino-
gen DMBA in a flux-density dependent
manner (9,10). These data prompted the
U.S. National Toxicology Program (NTP)
to initiate MF studies that were an attempt
to replicate the results obtained by the
Hannover group using the DMBA initia-
tion/promotion mammary gland tumor
model. The NTP studies were supported
under the Electric and Magnetic Fields
Research and Public Information Dissemi-
nation Program (EMF RAPID) and con-
ducted by Anderson et al. (11) at Battelle.
In contrast to the data from Löscher’s
group, the Battelle studies found no
evidence for a cocarcinogenic or tumor-pro-
moting effect of MF exposure (12,13). In
the present paper, the investigators from the
two groups discuss differences between their
studies that might explain the apparent dis-
crepancies between the results of MF expo-
sure. The present discussion is not only
relevant for the studies on the DMBA
model; it may be important for other MF
bioeffect studies because most reported bio-
effects of low-level MF are weak and thus
difﬁcult to replicate (3,4,14–18). 
Comparison of Experimental
Procedures Used in the
Studies
Table 1 compares the experimental parame-
ters between the two laboratories. 
Animal strain and source. In the
Hannover experiments, female SD outbred
rats were obtained from Charles River
(Hagemann, Extertal, Germany) and accli-
matized for at least 1 week before use in the
experiments. At onset of exposure, rats were
approximately 50 days of age (body weight
about 170–180 g). 
In the Battelle experiments, female SD
outbred rats were obtained from Charles
River Laboratory (Raleigh, NC) and accli-
matized for 13–15 days before use for the
experiments. At onset of exposure, rats were
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In line with the possible relationship between electric power and breast cancer risk and the under-
lying melatonin hypothesis, 50-Hz magnetic ﬁeld (MF) exposure at microtesla ﬂux densities for
either 13 or 27 weeks signiﬁcantly increased the development and growth of mammary tumors in
a series of experiments from Löscher’s group in Germany. Löscher’s group used the 7,12-
dimethylbenz[a]anthracene (DMBA) model of breast cancer in Sprague-Dawley rats. The ﬁnding
could not be replicated when a similar experimental protocol was used in a study conducted by
Battelle in the United States. In the present paper, investigators from the two groups discuss dif-
ferences between their studies that might explain the apparent discrepancies between the results.
These differences include the use of different substrains of Sprague-Dawley rats (the U.S. rats
were more susceptible to DMBA than the European rats), different sources for diet and DMBA,
differences in environmental conditions, and differences in MF exposure metrics. Furthermore,
the effects of MF exposure reported by Löscher’s group, albeit signiﬁcant, were weak. We also
discuss the general problem of replicating such weak effects. Key words: breast cancer, electric
power, electromagnetic ﬁelds, melatonin. Environ Health Perspect 108:797–802 (2000). [Online
21 July 2000]
http://ehpnet1.niehs.nih.gov/docs/2000/108p797-802anderson/abstract.html
Commentary50 ± 2 days of age (body weight approxi-
mately 175–185 g). 
Animal housing and diet. Animal caging
configurations were somewhat different
between the two laboratories: 9–10 animals
per cage (cage size 55 cm × 39 cm × 22 cm)
in the Hannover studies and 4 animals (cage
size 48 cm × 26.7 cm × 20.3 cm) or 5 ani-
mals (cage size 58.4 cm × 38 cm × 20.3 cm)
per cage in the Battelle studies. Diet also dif-
fered between the studies: Altromin 1324
was used in the Hannover studies and NIH
07 was used in the Battelle studies. In both
cases, food and water were available for the
rats ad libitum.
Animal room environment. Room tem-
perature (22.2 ± 1.5°C and 23–24°C;
Battelle and Hannover, respectively) and
humidity (50 ± 15% relative humidity) were
well-controlled and comparable between the
studies. With respect to light, 12 hr ﬂuores-
cent light per day with a range of 47–85 lux
at cage level (Battelle) or 30–38 lux at cage
level (Hannover) was followed by 12 hr dim
red light (< 0.1 lux) per day with comparable
light intensities.
Carcinogen dosage and administration
schedule. Each group used two protocols. In
the ﬁrst protocol, rats were administered 20
mg DMBA (four weekly gavage doses of 5
mg/rat in sesame oil). In the Battelle study, an
additional experiment was done with 4 week-
ly gavage doses of 2 mg DMBA in sesame oil.
In the second protocol, rats were treated once
with 10 mg DMBA (in sesame oil) by gavage.
Ninety-five percent pure DMBA was
obtained from Sigma (Deisenhofen,
Germany) for the Hannover and 98.6% pure
DMBA was obtained from TCI America
(Portland, OR) for the Battelle studies. 
Group size. Except for one experiment
(n = 36 rats), the Hannover study used 99
rats in all experiments discussed here. The
Battelle study had groups of 100 rats per
treatment group 
Exposure conditions. The Hannover
group studies used six identical exposure
chambers with four square coils each located
in the same room (three at each side) [Baum
et al. (19) and Mevissen et al. (20) provide
details]. Each chamber had room for four
cages (two levels with two cages each) with
9–10 animals per cage. Three of the chambers
were used for MF exposure and the other
three for sham exposure, i.e., both sham and
MF-exposed rats were in the same room dur-
ing the experiment; therefore, the environ-
mental conditions were the same for both
groups except for the MF. The investigators
were blinded with respect to sham and MF
exposure. Field characteristics in the experi-
ments with 100 µT were 50-Hz, horizontal
linear polarization, 100 µT root-mean-square.
The 50-Hz stray ﬁelds in the sham-exposure
coils were approximately 0.1 µT. In experi-
ments with 50, 10, or 0.3–1 µT, stray ﬁelds
for sham controls were correspondingly
lower. The earth static MF was approximately
40 µT, with the generated 50-Hz MF being
horizontal and parallel to the horizontal com-
ponent of the earth’s north/south MF (20).
Measurement of the electric ﬁeld in the expo-
sure and sham-exposure chambers did not
indicate any signiﬁcant differences between
exposed and sham-exposed locations.
Twenty-four-hour measurements showed that
under the conditions of the experiment the
MF exposure system produced a stable ﬂux
density of 100 µT and stable frequency of 50-
Hz with negligible harmonics and no power
spikes. MF exposure was 24 hr/day during the
experiments (minus time for weighing, tumor
palpation, cage cleaning, and cage rotation) 7
days/week for a total duration of either 13 or
27 weeks. In experiments with 20 mg DMBA
(4 weekly doses of 5 mg), the exposure was
started immediately after the ﬁrst administra-
tion of DMBA. In the experiment with one
administration of 10 mg DMBA, MF expo-
sure was started 1 week before DMBA
administration.
In the Battelle studies [the NTP (11),
Anderson et al. (12), and Boorman et al. (13)
provide details], the MF exposure system
consisted of four identical field-generating
coil sets, each associated with three animal
exposure racks in a single exposure room.
The sham control rats were housed in an
adjoining room in equivalent exposure racks.
Exposures were not conducted in a blinded
fashion, although tumor palpation, necrop-
sies, and histopathology were blinded. Rats
were exposed to < 0.06 µT (sham control),
100 µT, or 500 µT 50-Hz or 100 µT 60-Hz
horizontal linear MF. Exposure occurred for
18.5 hr/day, 7 days/week during the studies.
Each day the fields were turned off twice
(between 0700 and 1100 hr and from 1500
to 1630 hr) to provide access to animals for
husbandry and observation. In all experi-
ments, the MF exposure was started immedi-
ately after the ﬁrst DMBA application.
Quantification of mammary tumors.
During MF or sham exposure, rats were pal-
pated once a week for the detection of mam-
mary gland tumors in both studies. At the
end of the exposure period, a necropsy was
performed in all rats. In the Hannover group
studies, grossly recorded (macroscopically
visible) mammary tumors at time of necrop-
sy were used for calculation of tumor inci-
dence, multiplicity (number of tumors per
rat), tumor size (volume or weight), and site
of tumor development (location of tumors
within each rat’s six pairs of mammary
glands). In the six Hannover group studies
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Table 1. Comparison of experimental parameters utilized in the Hanover studies and the Battelle studies.
Study protocol
Experimental parameters Hanover Battelle
Experimental animals (rats)
Stock Sprague Dawley Sprague Dawley
Sex Female Female
Source Charles River, Extertal, Germany Charles River, Raleigh, NC
Body weight at onset of exposure 170–180 gm 175–185 gm
Housing/maintenance
Quarantine/acclimation period 1 Week 15 Days
Rats/cage (n)9 –10 4–5
Cage size (cm) 59 × 39 × 22 48 × 26 × 20 (four rats)
58 ×  38 × 20 (ﬁve rats)
Diet Altromin 1324 NIH 07
Bedding Corn cob Sani chips
Room temperature 23–24°C 22.2 ± 1.5°C
Humidity Approximately 50%  50 ± 15%
Lights (ﬂuorescent)
Cycle (day/night) 12/12 12/12
Intensity 30–38 lux 47–85 lux
Red light intensity < 0.1 lux < 0.1 lux
DMBA treatment
Source/purity Sigma (95%) TCI America (98.6%)
Age of rats at ﬁrst DMBA treatment 52 ± 2 days 50 ± 2 days
Frequency/amount of DMBA  4 × 5 mg/rat 4 × (5 and 2) mg/rat
(13-week studies)
Frequency/amount of DMBA  1 ×  10 mg/rat 1 × 10 mg/rat
(26-/27-week studies)
Magnetic ﬁeld exposure
Frequency 50 Hz 50 and 60 Hz
Magnetic ﬁeld intensity 1, 10, 50, and 100 µT 100 and 500 µT
Days/week 7 7
Hours/day 23–24 18.5
Time of exposure Continuous 1100–1400 hr, 1530–0700 hr
Study length 13/27 Weeks 13/26 Weeksdiscussed here, a microscopic examination of
all grossly recorded tumors was done in three
studies (19,21,22); in the other three studies
only small tumors were microscopically
examined to confirm the diagnosis (most
mammary tumors were so large that they
could be conﬁdently diagnosed without his-
tology). In two of the six studies (19,21),
serial sections of all mammary glands were
histologically examined (after staining with
hematoxylin and eosin) to also detect very
small tumors (only detectable at the micro-
scopic level) and hyperplasias that were not
grossly recorded during necropsy. 
In the Battelle studies, masses were iden-
tiﬁed by speciﬁc lesion in each rat during the
weekly palpations. Two individuals each pal-
pated half of the rats each week, alternating
by group of rats. Sizes were determined by
comparison with wooden spheres of deﬁned
size. At the time of necropsy the clinical
observations were available to the pathologist
for each animal. The mammary glands and
associated skin were transilluminated to iden-
tify all potential tumors and a few additional
masses were found. Masses were measured in
two directions and collected in formalin,
stained by hematoxylin and eosin, and exam-
ined histologically. Each gross lesion was
uniquely identiﬁed and the diagnosis veriﬁed
by microscopic examination.
Comparison of Study Results 
Hannover studies. MF exposure for 13 weeks
at ﬂux densities of 0.3–1 µT or 10 µT did not
exert any significant facilitatory effect on
mammary carcinogenesis in the DMBA
model, although a trend to increased tumor
incidence was seen in the 10 µT experiment
(23). In the four experiments with 50 or 100
µT, MF exposure signiﬁcantly increased the
number of mammary tumors detected by pal-
pation during exposure (19,20,22,24,25), but
only the necropsy data will be discussed here.
As shown in Table 2, MF exposure at ﬂux
densities of 50 and 100 µT exerted a signiﬁ-
cant effect on the incidence of grossly record-
ed mammary tumors after both 13 and 27
weeks of exposure, independent of the
DMBA dosing and administration protocol
used. Tumor multiplicity was not signiﬁcant-
ly affected by MF exposure. Tumor size was
signiﬁcantly increased in only one experiment
with 100 µT (19), but not significantly
altered by MF in the other experiments. In
the study with 27 weeks of MF exposure (22),
the most pronounced MF effect on tumor
incidence in site of tumor development (loca-
tion in which of each rat’s six pairs of mam-
mary glands) was determined in the cranial
thoracic complex (L/R 1). Tumor incidence
in this complex was 30 of 99 MF-exposed rats
compared to 18 of 99 sham-exposed animals
(p < 0.05). After reexamination of one of the
previous studies with 100 µT MF exposure
(20), a similar enhanced susceptibility of L/R
1 to increased tumor incidence in response to
MF exposure was found; 50 of 99 exposed
rats had tumors in L/R 1 compared to 36 of
99 controls (p < 0.05). 
One of the experiments with 100 µT
exposure for 13 weeks included a complete
histologic examination of the mammary
gland using serial sections of all mammary
complexes (including those without grossly
recorded mammary tumors) (19). This resul-
ted in the histologic diagnosis of 65 tumors
(compared to 51 grossly recorded tumors) in
the MF-exposed group and 57 tumors (com-
pared to 34 grossly recorded tumors) in the
sham group; the difference between groups
was not significant. The interpretation of
this finding, i.e., no significant intergroup
difference in incidence of all tumors (includ-
ing those only detectable at the microscopic
level) but a signiﬁcant intergroup difference
in incidence of grossly recorded tumors, was
that MF exposure increased tumor growth
(so that more tumors were at the macroscop-
ic level at time of necropsy) but not the over-
all incidence of tumors. Furthermore, MF
exposure enhanced tumor progression
because the incidence of malignant tumors
(adenocarcinoma) was signiﬁcantly higher in
the MF-exposed group (19).
Battelle study. In the eight Battelle exper-
iments with 100 or 500 µT, MF exposure
did not signiﬁcantly increase the number of
mammary tumors detected by palpation dur-
ing exposure (11–13). We further discuss
only the data from necropsy. As shown in
Table 3, MF exposure at ﬂux densities of 100
or 500 µT did not signiﬁcantly increase the
incidence of grossly recorded mammary
tumors after either 13 or 26 weeks of expo-
sure. Furthermore, no signiﬁcant effects on
tumor multiplicity or tumor size were
observed. In general, the U.S. SD rats used
in the Battelle studies (Table 3) appeared to
be more sensitive to DMBA than the
European SD rats used in the Hannover
experiments (Table 2), as indicated by the
higher mammary tumor incidence in control
groups of the Battelle study. Although
considered unlikely, the differences could
also result from variations in the purity,
concentration, or activity of the DMBA.
Alternatively, some differences in tumor
yield might result from differences in dosing
regimes or technique. Clearly, when the
lower dose of DMBA was used in the
Battelle studies (i.e., 4 × 2 vs. 4 × 5 mg/dose;
Table 3), the tumor incidence and multiplic-
ity (at 13 weeks) was more comparable with
the values observed at the higher doses in the
Hannover studies. In the Battelle study, an
independent laboratory analyzed the DMBA
dose solutions and found that they were
99.8–101.4% of target concentration.
Discussion of the Differences
between the Studies
In view of the Hannover ﬁndings indicating
signiﬁcant effects of 50-Hz MF exposure on
mammary carcinogenesis (thereby supporting
the melatonin hypothesis), it was important
to examine whether these ﬁndings could be
reproduced by other laboratories using the
same or similar experimental protocols as in
the Hannover experiments. Respective stud-
ies conducted at Battelle demonstrated no
signiﬁcant increases in mammary cancer inci-
dence, multiplicity, or growth in rat groups
exposed to either 50- or 60-Hz MF (11). 
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Table 2. Incidences of neoplasms of the mamma-
ry gland observed grossly at necropsy in female
SD rats in the experiments of Löscher’s group.
Dosing Incidence of 
protocol mammary tumors
(DMBA), Rats/group MF/
MF exposure  (n)% control
4 ×  5 mg/rat, 13 weeks
Sham exposure 21/36 58
0.3-1 µT, 50-Hz 21/36 58 1.0
4 ×  5 mg/rat, 13 weeks
Sham exposure 60/99 61
10 µT, 50-Hz 66/99 67 1.1
4 ×  5 mg/rat, 13 weeks
Sham exposure 55/99 56
50 µT, 50-Hz 69/99* 70* 1.25*
4 ×  5 mg/rat, 13 weeks
Sham exposure 34/99 34
100 µT, 50-Hz 51/99* 52* 1.53*
4 ×  5 mg/rat, 13 weeks
Sham exposure 61/99 62
100 µT, 50-Hz 82/99* 83* 1.34*
1 ×  10 mg/rat, 27 weeks
Sham exposure 50/99 51
100 µT/ 50-Hz 64/99* 65* 1.27*
Data from Baum et al. (19), Mevissen et al. (20,23,25),
Löscher et al. (21,24), and Thun-Battersby et al. (22). 
*Signiﬁcantly different from control (p at least < 0.05).
Table 3. Incidences of neoplasms of the mamma-
ry gland observed grossly at necropsy in female
SD rats in the Battelle study.
Dosing protocol Incidence of carcinomas
(DMBA), MF Rats/group  MF/
exposure (n)% control
4 ×  5 mg/rat, 13 weeks
Controls 92/100 92
100 µT, 50-Hz 86/100 86 0.93
500 µT, 50-Hz 96/100 96 1.04
100 µT, 50-Hz 96/100 96 1.04
4 ×  2 mg/rat, 13 weeks
Controls 43/100 43
100 µT, 50-Hz 48/100 48 1.12
500 µT, 50-Hz 38/100 38 0.88
1 ×  10 mg/rat, 26 weeks
Controls 96/100 96
100 µT, 50-Hz 90/100 90 0.94
500 µT, 50-Hz 95/100 95 0.99
100 µT, 60-Hz 85/100* 85* 0.86*
Data from the National Toxicology Program (11),
Anderson et al. (12), and Boorman et al. (13). 
*Signiﬁcantly different from control (p < 0.05).During the design of the Battelle study,
investigators from the Hannover group were
asked to review the study protocol to ensure a
faithful replication between the two laborato-
ries. In addition to using protocols similar to
Löscher’s initial experiments (19–21,24,25)
with four weekly gavage doses of 5 mg
DMBA and MF exposure for 13 weeks at
100 µT and a frequency of 50-Hz (European
power-line frequency), the Battelle study also
included experiments with 60-Hz (U.S.
power-line frequency), higher flux density
(500 µT), and a more traditional DMBA
protocol (one administration of 10 mg/rat
and necropsy after 26 weeks). The Hannover
study using one administration of 10 mg
DMBA and necropsy after 27 weeks of MF
exposure was ﬁnished after the Battelle study
and we included it here for comparison and
discussion.
Despite comparable experimental
designs and an attempt to conduct the
Battelle study as similarly as possible to the
initial experiments of the Hannover group,
there are several differences between the
studies that may have contributed to the dif-
ferences in outcome. Furthermore, we dis-
cuss some factors that might be important
for detectability of MF effects. 
Variability of tumor incidence in sham
control groups. Significant effects on the
incidence of grossly recorded mammary
tumors were obtained in all of the Hannover
experiments with 50 or 100 µT MF expo-
sure (Table 2). The first experiment with
four weekly DMBA administrations and 100
µT exposure for 13 weeks (19,24) was
repeated once to ensure the reproducibility
of the MF effect, again resulting in a signiﬁ-
cant increase in mammary tumor incidence
(20). In sham controls of the six experiments
shown in Table 2, there was considerable
variability in tumor incidence rates, which
has been suggested to reﬂect seasonal varia-
tion in the sensitivity of the mammary gland
to DMBA (26). This was one reason to
include sham controls together with each
MF study. Because tumor incidence in MF-
exposed rats was greater than concurrent
control in five of six experiments and was
never less than control incidence, it is
unlikely that the significant differences
between sham and MF-exposed groups were
the results of uncontrolled variability. 
Variability in tumor incidence in con-
trol groups was not studied in the Battelle
experiments for the different DMBA dosing
protocols.
Effect of background tumor incidence on
detectability of MF effects. The effects of 100
µT MF exposure in the Hannover experi-
ments with four weekly gavage doses of 5 mg
DMBA per rat, albeit signiﬁcant, were not
marked (Table 2). This was a reason to
undertake a more recent study in which MF
exposure was started 1 week before DMBA
application. The DMBA dose was decreased
to one intragastric dosing with 10 mg/rat, and
the duration of MF exposure was increased to
a total of 27 weeks because it was thought
that these protocol modifications could
enhance the effect of MF exposure on mam-
mary carcinogenesis (22). Thirteen weeks
after DMBA application (i.e., 14 weeks after
the initiation of MF exposure), tumor inci-
dence was 8% in controls but 23% in MF-
exposed rats (data based on palpation), thus
indicating that tumor incidence in MF-
exposed rats was increased 3-fold (p = 0.003).
Because tumor incidence in sham controls 13
weeks after application of DMBA with 20 mg
DMBA was substantially higher compared to
tumor incidence 13 weeks after 10 mg
DMBA, this might indicate that the magni-
tude of the MF effect at the same duration of
exposure depends on the background (con-
trol) tumor incidence in this model; i.e., the
lower the control tumor incidence the higher
the increase in tumor incidence by MF expo-
sure. When we plot the data from the three
experiments with 100 µT MF exposure as
shown in Figure 1, there appears to be an
inverse relationship between control incidence
and the magnitude of the MF effect on tumor
incidence 13 weeks after DMBA application.
The marked difference in incidence of palpa-
ble tumors between MF-exposed and sham-
exposed groups 13 weeks after administration
of 10 mg DMBA was reduced during further
exposure (22), suggesting that the MF effect
was due to a tumor growth-enhancing action
rather than to a cocarcinogenic effect. 
In the ﬁrst Battelle 13-week study, back-
ground (control) tumor incidence was 92%
when a DMBA dose comparable to that in
the Hannover studies was used (4 ×  5 mg
DMBA per rat). In the Battelle 26-week
study, the control tumor incidence was 96%
at the end of the 26-week period using 1 ×
10 mg/rat. Because of the high incidence of
tumors in both cases, the sensitivity of these
experiments to detect cocarcinogenic effects
of MF exposure at the end of the study was
low. In the study using 4 ×  2 mg DMBA per
rat, a lower background tumor incidence
(43%) was obtained at 13 weeks; this was
generally more comparable to the incidences
observed in the Hannover studies. None of
the Battelle studies, using either palpation
data throughout the course of the experi-
ments or the conﬁrmatory data at necropsy,
showed significant MF effects on grossly
recorded mammary tumors. 
Effect of location of mammary tumors on
detectability of MF effects. In the Hannover
experiment with 10 mg/rat and 27 weeks of
MF exposure, the development of mammary
tumors was affected unequally across the six
mammary complexes of the female rat (the
cranial thoracic complex is particularly sensi-
tive to MF exposure). A similar enhanced
susceptibility of this mammary complex to
MF exposure was also found by reevaluating
one of the previous Hannover experiments
with 100 µT (20). Previous studies showed
that not all of the mammary glands respond
to the administration of DMBA in the same
fashion; tumor incidence in thoracic mam-
mary glands is higher than in the abdominal
glands (27–29). It is thought that this differ-
ent carcinogenic response is due to the asyn-
chronous development of mammary glands
in different topographic areas; thoracic glands
lag behind in development and retain a high-
er concentration of terminal end buds (i.e.,
the site of origin of mammary carcinomas)
(28). Recent experiments from the Hannover
laboratory (30) indicate that the L/R 1s are
particularly sensitive to increased proliferation
in response to 50-Hz, 100 µT MF exposure,
which might explain the higher susceptibility
of these complexes to tumor-promoting
effects of MF exposure. These data thus
strongly indicate that not only the back-
ground (control) tumor incidence but also the
site of origin of mammary carcinomas may
possibly influence the extent to which MF
exposure increases mammary tumorigenesis in
the DMBA model.
In the Battelle studies, no data on the
location of mammary tumors were reported
for the different MF exposure experiments.
Differences in substrains of rats used in
the studies. The Battelle study used SD rats
obtained from a U.S. supplier, whereas
Commentary • Anderson et al.
800 VOLUME 108 | NUMBER 9 | September 2000 • Environmental Health Perspectives
Figure 1. Relationship between control incidence
of mammary tumors and increase in tumor inci-
dence by MF exposure. Data from three separate
experiments with 50-Hz MF exposure at 100 µT. In
each experiment, a sham control group of 99 rats
was exposed together with an MF group of 99 rats.
The sham control mammary tumor incidence is
plotted against the MF-induced increase in mam-
mary tumor incidence determined 13 weeks after
application of DMBA in the same experiment. Data
adapted from Thun-Battersby et al. (22). 
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Hannover studies used animals procured
from a German supplier. Using the same
dosing level, 4 × 5 mg/rat DMBA, a much
higher control incidence of mammary
tumors (92%) was observed in the experi-
ments at Battelle than in the experiments in
Hannover (34–62% control incidence; Table
2). The same was true for the Battelle experi-
ment with 10 mg DMBA and 26 weeks of
exposure (control tumor incidence was 96%
at the end of the study compared to 51% in a
similar experiment using a comparable dos-
ing level and duration as the Hannover
group). The high percentage of animals with
tumors at the end of the two Battelle studies,
although not precluding differentiation
between groups in rate of tumor develop-
ment or tumor multiplicity, would generally
mask any discrimination of tumor incidence
in exposed versus control groups. The high
control incidence led Battelle investigators to
perform the additional study using four
weekly doses of 2 mg DMBA. The latter
experiment is presumably the most impor-
tant of the Battelle studies because the con-
trol tumor incidence was comparable (43%)
to that of the Hannover experiments, thus
allowing the discrimination of any incidence-
enhancing MF effect. However, no MF effect
was observed in this study as well. 
The data from the two labs suggest that
the rats used in the Battelle study might be
more sensitive to the carcinogenic effect of
DMBA than the European rats but possibly
less sensitive to any inﬂuence of MF expo-
sure. It has previously been demonstrated
that there are inherent differences between
substrains of SD outbred rats obtained in the
United States and those from Europe with
regard to neoplastic response of mammary
tissue to DMBA and their response to radia-
tion (32). Outbred rats of the same strain
obtained from different breeders may differ
markedly in various genetic factors (33);
therefore, different genetics of the SD rats
used in the Battelle and Hannover studies
present a reasonable candidate for the signiﬁ-
cantly differing results. 
The likely involvement of substrain differ-
ences in the Hannover and Battelle experi-
ments prompted the Hannover group to
search for substrains of SD rats that are insen-
sitive to MF exposure under the conditions of
the Hannover studies. Last year, a substrain of
SD rats was found that signiﬁcantly differs in
sensitivity to both DMBA and 50-Hz MF
from the substrain used in the published
reports from the Hannover group, thus sub-
stantiating that the genetic background plays
a pivotal role in the cocarcinogenic effects of
MF exposure (34).
Dietary differences. Diet may also
explain the differing study results. Diet has a
substantial impact on the sensitivity of rats
to DMBA-induced cancer (35–37). Food
was procured from different sources with
slight differences in compositions of the diet.
Furthermore, to avoid any metal in the
exposed cages, rats in the Hannover studies
were offered food in acrylic feeding dishes
with perforated lids (24) so that access to
food was somewhat more restricted for the
rats compared to conventional feeding
devices. Although body weight gain was nor-
mal in these rats, any restriction of calorie
intake decreases the sensitivity of rats to
chemically induced breast cancer (38).
Animal housing. An interesting and
potentially important difference between
studies in the two laboratories was the num-
ber of rats housed per cage. Caging in both
systems was in compliance with the recom-
mended housing space for laboratory animals
(39). However, with fewer animals per cage
in the Battelle studies (and correspondingly
more ﬂoor space per animal), there may be
some difference in animal stress between the
studies. Currently no data are available to
address the potential inﬂuence of these differ-
ences on any EMF effects in the DMBA
mammary cancer model.
DMBA sources. Although slight differ-
ences in purity of the DMBA were recorded,
the more signiﬁcant potential for an effect on
experimental outcome is in the preparation
of the DMBA dose solution. If significant
differences exist between the dosing effective-
ness of the two labs it might provide some
explanation for the marked difference in
tumor level in control rats but it would not
explain the differences observed with field
exposure. 
Location of controls. There were differ-
ences in control exposures (sham exposure in
identical coils in the same room in the
Hannover experiments vs. control rats in an
adjoining room in the Battelle study). These
differences would seem to provide a more
relevant explanation, however, if the results
were the opposite of those obtained (i.e.,
with MF effects in the Battelle studies and
no effects in the Hannover studies).
Lighting conditions. Some experiments
have suggested that MF effects can be affect-
ed by light level and light spectral composi-
tion, which were only partly characterized in
the studies discussed here. However, the
light–dark cycle was equivalent in both stud-
ies at 12/12 hr light/dark. A dim red light
was used during the dark period.
MF exposure metrics. Although both
studies used linearly polarized sine wave MF,
the effects of other aspects of MF exposure
were not considered in sufficient detail in
the two studies. These aspects involve geo-
magnetic field, transients, and exposure
duration [reviewed  by Polk (40), Misakian
et al. (41), and Valberg (42)]. 
Different physical models for MF–biosys-
tem interaction have been proposed that
suggest outcomes which depend on the mag-
nitude of the static (geomagnetic) ﬁeld and its
direction relative to an MF in the microtesla
range. The magnitude and direction of the
geomagnetic field relative to the MF have
been described for the exposure conditions of
the Hannover experiments (20) and for the
Battelle study (43). This argument, as a possi-
ble explanation for the differences in results, is
weakened by the housing conﬁguration that
allows free and random movement of the ani-
mals during exposure.
Biologic effects have also been suggested
as possibly arising from power system tran-
sients of increased intensity. Transients, as
well as amplitude variations, could be caused
by turning equipment on and off in the
building complex where the experiments
were performed. Measurements of transients
were not performed and not corrected for in
the Hannover studies. Investigators at
Battelle took a slightly different approach:
the exposure system was supplied power
through line conditioners that were used to
eliminate peak transients from the exposure
system operation.
Another aspect of exposure that was dif-
ferent between the two labs was exposure
duration. Daily exposure in the Hannover
studies extended for ≥ 23 hr/day, whereas
exposure in the Battelle studies was 18.5
hr/day. The differences in daily exposure
duration resulted in > 400 hr less exposure
in Hannover during a 13-week study.
Because of the importance of MF expo-
sure metrics, a plan to characterize the ﬁelds
in more detail in the two laboratories would
contribute to a determination of whether the
differing results might be ascribed to differ-
ences in exposure metrics.
Statistics. Another topic relevant to the
present discussion is the statistical chance to
reproduce weak effects as reported by the
Hannover group even when all factors
described here are dealt with in an indepen-
dent replication study by another laboratory.
For instance, taking the experiment from the
Hannover group with the most marked
effect, i.e., the 100 µT experiment with 51
of 99 exposed rats with mammary gland
tumors versus 34 of 99 for the unexposed
controls (Table 2), the chance of repeating
the effect with 100 rats per group is only
75%. To increase the chance much above
this would require a large increase in group
size. This should be carefully considered in
the discussion of replicate experiments and
in the protocol design of future studies. 
Conclusions
Two carefully conducted series of studies on
MF effects in the rat DMBA mammary
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The critical question is whether the results
observed by the Hannover group are real or
are due to chance or methodologic biases.
The fact that tumor incidence in MF-
exposed groups in the six experiments carried
out by the Hannover group was never below
sham controls but was above controls in ﬁve
experiments argues against chance as a likely
explanation for the ﬁndings. Furthermore, in
view of the blinded conditions under which
the Hannover experiments were conducted,
methodologic biases are also unlikely to be
determinant in the ﬁndings. Assuming that
the positive ﬁndings in the Hannover experi-
ments are real, the lack of replication by the
Battelle experiments suggests that such a pos-
itive MF effect can be detected only under
certain experimental conditions. In the pre-
sent paper we have presented a number of
conditions that could potentially explain the
differing results between the Hannover and
Battelle studies. 
The issue of MF exposure and risk of
breast cancer is an important, not yet com-
pletely resolved issue that requires further
study to address apparent conﬂicts between
carefully conducted comparable studies. The
positive results from the Hannover experi-
ments would be strengthened through an
identiﬁcation of mechanisms of action for the
increased growth rate of DMBA-initiated
tumors. In this respect, the effect of MF
exposure on ODC activity in mammary tis-
sue (30,44) should be noted, suggesting that
it might be advantageous to expand end
points in in vivo studies to include biochemi-
cal parameters relevant to possible carcino-
genic mechanisms of MF to increase the
potential for reproducing positive MF effects.
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